ASCO: Radium-223 Prolongs Survival Time for Patients with Bone-Metastatic Castration-Resistant Prostate Cancer

Share this content:

(CHICAGO, IL) – Radium-223 chloride therapy significantly prolongs median overall survival (OS) time for men with castration-resistant prostate cancer (CRPC) bone metastasis, according to a randomized, double-blind, multinational Phase 3 trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.

“Radium-223, a first-in-class alpha emitter, may provide a new standard of care for the treatment of CRPC patients with bone metastasis,” said lead author Chris Parker, MD, Consultant Clinical Oncologist at the Royal Marsden NHS Foundation Trust, Sutton, UK. 

Eligible patients had confirmed symptomatic CRPC with 2 or more bone metastases, no known visceral metastasis, and were not currently taking docetaxel. Patients were randomized 2:1 to receive 6 intravenous administrations of Ra-223 (50kBq/kg) every 4 weeks (n=614) or matching placebo (n=307).

Compared to placebo, radium-223 significantly prolonged median OS by 3.6 months (14.9 vs. 11.3 months; HR=0.695; P=0.00007) and was associated with a 30.5% reduction in the risk of death. Radium-223 also significantly prolonged median time to first skeletal related event (SRE) by 5.5 months (HR=0.64; P<0.0001), Dr. Parker and colleagues reported.

Grade 3/4 toxicities were similar between the radium-223 and placebo arms (neutropenia, 2% vs. 1%; thrombocytopenia, 6% vs. 2%). Grade 3/4 anemia occurred in 13% of patients in each study arm.

“Further follow-up in all randomized patients continues to show highly favorable safety profile,” Dr. Parker said. “Safety and tolerability of Ra-223 remained favorable, with low myelosuppression.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs